An integrated valuation model for payer and investor
Background In order to optimize positioning and associated drug price for both payer and investor, it is for a company essential to forecast the potential market access attractiveness for the new drug for different indications at the early onset of the clinical development program. This analysis mus...
Saved in:
| Main Authors: | Mark Nuijten, Stefano Capri |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Journal of Market Access & Health Policy |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/20016689.2022.2080631 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pricing of orphan drugs in oncology and rare diseases
by: Mark Nuijten, et al.
Published: (2020-01-01) -
Pricing Zolgensma – the world’s most expensive drug
by: Mark Nuijten
Published: (2022-12-01) -
Are payers treating orphan drugs differently?
by: Joshua P. Cohen, et al.
Published: (2014-01-01) -
Valuation of Medical Innovation Handling with Uncertainty and Risk
by: Mark Nuijten, et al.
Published: (2024-08-01) -
Proposed changes to the reimbursement of pharmaceuticals and medical devices in Poland and their impact on market access and the pharmaceutical industry
by: Karolina Badora, et al.
Published: (2017-01-01)